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Background: Current hepatitis C virus (HCV) therapies may cure 60% of infections. They are often
contraindicated or poorly tolerated, underscoring the need for safer and more effective drugs. A novel,
a-ketoamide-derived, substrate-based inhibitor of the HCV serine protease (SCH446211) was developed.
Compared with earlier reported inhibitors of similar chemical class, it has a P1
0–P20 extension which
provides extended interaction with the protease active site. The aim of this study was to evaluate the
in vitro antiviral activity of SCH446211.
Methods: Binding constant of SCH446211 to HCV NS3 protease was measured with the chromogenic
substrate in vitro cleavage assay. Cell-based activity of SCH446211 was evaluated in replicon
cells, which are Huh-7 hepatoma cells stably transfected with a subgenomic HCV RNA as reported
previously. After 72 h of incubation with SCH446211, viral transcription and protein expression were
measured by real-time RT–PCR (TaqMan), quantitative in situ hybridization, immunoblot and indirect
immunofluorescence.
Results: The binding constant of SCH446211 to HCV NS3 protease was 3.8 –0.4 nM. HCV replication
and protein expression were inhibited by SCH446211 in replicon cells as consistently shown by
four techniques. In particular, based on quantitative real-time RT–PCR measurements, the IC50 and IC90
of SCH446211 were estimated to be 40 –20 and 100– 20 nM (n = 17), respectively. Long-term culture
of replicon cells with SCH446211 reduced replicon RNA to <0.1 copy per cell. SCH446211 did not show
cellular toxicity at concentrations up to 50 mM.
Conclusions: SCH446211 is a potent inhibitor of HCV protease in vitro. Its extended interaction with
the HCV NS3 protease active site is associated with potent in vitro antiviral activity. This observation
is potentially a useful guide for development of future potent inhibitors against HCV NS3 protease.
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Introduction
Chronic infection with hepatitis C virus (HCV) affects 170
million people worldwide. HCV shows a remarkable tendency to
establish persistent infections and chronic liver disease, ultimately
leading to cirrhosis and hepatocellular carcinoma.1 Current
standard therapy with peg-interferon and ribavirin has a sustained
virological response (SVR) rate of 70–80% in genotypes 2 or 3 in
24 weeks of therapy.2 Its results are less satisfactory with
genotype 1, SVR is 50% and requires longer treatment
(48 weeks), although a 24 week schedule has been shown to be
effective in a subgroup of patients with low viral load who
achieved very rapid virological response.3 Both interferon-a
(IFN-a) and ribavirin cause significant side effects, often leading
to dose reduction or premature discontinuation of therapy. Lack of
a complete virological response, relapse and toxicity concerns still
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represent major barriers to treatment in a substantial proportion of
patients. Thus, more effective and better tolerated drugs are
needed to treat chronic hepatitis C.
HCV is a member of the Flaviviridae family with a positive-
stranded RNA genome of 9.6 kb.4 Its genome encodes a
3000 amino acid polyprotein, which is processed co- or post-
translationally by host and viral proteases.5 The NS3 serine
protease, comprising the 189 N-terminal amino acids of protein
NS3, is essential to HCV replication. It forms a heterodimer with
NS4A, which is a cofactor for protease activity. Following the
cis cleavage of NS3-NS4A site, NS3 protease cleaves the NS4A-
NS4B, NS4B-NS5A and NS5A-NS5B sites to release the non-
structural proteins.6–10 The NS3 serine protease is constituted
of two six-stranded b-barrel trypsin-like folds, defining a crevice
in which substrate interactions with the catalytic triad take
place.11,12 The shallowness and solvent accessibility of this
pocket have made the development of effective inhibitors a
challenging task.
The lack of a robust tissue culture system and a small
animal model had hindered the pre-clinical evaluation of HCV
inhibitors. The recent development of in vitro HCV infection
systems13–15 will provide an opportunity to evaluate HCV
inhibitors in the entire HCV life cycle. Earlier development of
HCV replicon has proved to be an invaluable tool to evaluate new
inhibitors of HCV replication.16–18 Recently, proof-of-concept
clinical trials were reported with HCV NS3 protease inhibitors
BILN-2061, VX-950 and SCH503034.19–21 All these three
compounds have submicromolar IC90 in the replicon assay and
markedly reduced serum viral load in patients chronically infected
with HCV. Resistance mutations against each of these inhibitors
were developed. A156T/V conferred strong resistance to all
three compounds, while D168V was resistant to BILN2061 and
remained sensitive to VX-950 and SCH503034. The overlapp-
ing and distinct resistance profiles emphasizes the importance
in versatility of inhibitors to optimize potency and reduce
the emergence of resistance. Here, we report the in vitro
antiviral activity of SCH446211 (SCH6), a new ketoamide
peptidomimetic inhibitor of NS3. Our results demonstrate that
SCH446211 is a potent inhibitor of HCV protease in vitro. Its
extended interaction with HCV NS3 protease is associated with
potent in vitro antiviral activity and its resistance profile is also
discussed.
Materials and methods
HCV NS3/NS4A protease chromogenic assay
The continuous chromogenic assay for HCV protease was reported
previously.22 Briefly, protease NS4A21–32-GSGS-NS33–181 was added
to assay buffer containing peptide substrate linked to chromophore
Ac-DTEDVVP(Nva)-O-PAP. The peptide sequence is derived from
the NS5A-NS5B junction where the C-terminal group is coupled to
chromophoric phenylazophenol (PAP). Serial diluted inhibitor was
mixed with protease. The assay was performed at 30C in 96-well
microtitre plates. The reactions were monitored at 30 s intervals for
1 h by reading the absorbance at 370 nm in a Spectromax Plus
microtitre plate reader (Molecular Devices, Sunnyvale, CA, USA).
The data were fitted to the two-step slow-binding inhibition model
of Morrison and Walsh P = vst + (v0 – vs)(1 – e
–kt)/k using SAS
version 8.0 (SAS Institute Inc.) The overall K*i was calculated from
the estimated steady-state velocities fvs ¼ V maxS/½Kmð1þ I/K*i Þg.
Replicon cells and treatment with SCH446211
The replicon cell clone 16 contains identical HCV replicon RNA
sequences as reported,16 except for the incorporation of adaptive
mutation(s) S1179I.17 The replicon clones were generated by
transfection of replicon RNA followed by 0.5 mg/mL of G418
selection. The replicon cells were routinely maintained with DMEM
medium supplemented with 4 mM L-glutamine, 1.8 mM sodium
bicarbonate, 1· non-essential amino acids and 1 mM sodium pyruvate
(Mediatech, VA, USA) on collagen-coated plates (BD Biosciences
Pharmingen, CA, USA).
For real-time RT–PCR (TaqMan), 4000 cells were seeded in a
96-well plate in DMEM medium containing 0.5 mg/mL of G418.
SCH446211 was added to the medium in concentrations from 5 mM
to 10 nM in the presence of 5% FCS, 0.5 mg/mL of G418 and 0.5%
DMSO. SCH446211 and medium were refreshed every day for 72 h.
For in situ hybridization, immunoblot and immunofluorescence,
replicon cells were plated at 3 · 105 cells per 100 mm tissue culture
dish. After 24 h, SCH446211 was added to the cells at final
concentrations of 50, 100 and 500 nM with 10% fetal bovine serum,
0.5% DMSO and 1 mg/mL of G418 (all from Invitrogen, Basel,
Switzerland). SCH446211 was refreshed every 24 h. After 72 h, the
cells were trypsinized and processed.
Real-time RT–PCR
The 96-well plates were aspirated and washed. Cell-cDNA buffer
(Ambion, TX, USA) (30 mL) was added to each well and heated at
75C for 5 min. Lysate (1 mL) was added to real-time RT–PCR
(TaqMan) reactions containing 1· RT–PCR master mix (Applied
Biosystems, CA, USA), RNase inhibitor, 50 mM 5B forward
(50ATGGACAGGCGCCCTGA) and reverse (50TTGATGGGCAGC-
TTGGTTTC) primers, 5B probe (50CACGCCATGCGCTGCGG-
FAM) and 1· GAPDH primer and probe mixture (Applied Biosys-
tems). The PCR reactions were run on an ABI PRISM 7900HT
Sequence Detection System using the following program: 48C for
30 min, 95C for 10 min, and 40 cycles of 95C for 15 s followed
by 60C for 1 min. Amplification of HCV RNA was linear over
five logs and the detection sensitivity was estimated to be 500 RNA
copies per reaction with cell lysate and 10 copies per reaction with
purified RNA.
The difference in cycle numbers (CT) needed to amplify the NS5B
and GAPDH to the threshold level (DCT), was plotted against the log
of compound concentrations and fitted to the sigmoid dose–response
model using SAS version 8.0 (SAS Institute) or PRISM (Graphpad
Software Inc.). IC50 and IC90 indicate the drug concentrations needed
to achieve 2-fold (50%) and 10-fold (90%) inhibition, respectively,
compared with no treatment.
HCV RNA by in situ hybridization
Cells were collected in 150 mL of PBS after drug treatment; 20 mL
(50 000 cells) was layered onto poly-L-lysine-coated slides (Kindler
GmbH & Co. Freiburg, Germany) and dried. The slides were fixed,
washed and denatured. NS3 coding region was cloned into pGM
vector under the T7 promoter, linearized with SpeI (Promega, Catalys
AG, Wallisellen, Switzerland) and used for in vitro synthesis
of 1028 base long, [35S]CTP-labelled RNA of antigenomic
polarity, according to standard protocols (specific activity: 0.1–
0.2 · 108 cpm/mg of RNA). The in situ hybridization procedure
followed standard protocols. Cells were stained with H&E and
visually inspected for autoradiographic silver grain density assess-
ment. At least 20 cells were counted by two independent observers,
and results expressed as mean (–SD) autoradiographic silver grain
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number per cell, after subtracting the average grain number per
untransfected cell, hybridized and processed in parallel. Differences
between experiments were assessed by the Student’s t-test.
Antibodies
A rabbit polyclonal antibody was raised against NS3 protein.
A monoclonal antibody 5B-3B1 directed against HCV NS5B
protein and the antibody against b-actin were kindly provided by
Dr D. Moradpour (Lausanne, Switzerland) and Dr C. Chaponnier
(Geneva), respectively.
Immunoblot
Cells were lysed in 250 mM Tris–HCl, pH 6.8, 500 mM DTT, 10%
SDS, 0.5% Bromophenol Blue and 50% glycerol. Samples were
boiled, loaded onto a 12% polyacrylamide gel and separated by
electrophoresis. Proteins were transferred onto nitrocellulose mem-
brane (Millipore, Milian, Geneva, Switzerland). Membranes were
probed with primary antibody at 1:12, 1:1000 and 1:10 000 dilutions
for anti-NS5B, anti-b-actin and anti-NS3 antibodies, respectively,
followed by incubation with horseradish peroxidase-conjugated
secondary antibody (Bio-Rad, Reinach, Switzerland) diluted 1:3000
in washing buffer. Proteins were revealed by chemiluminescence
using a commercially available kit (ECL, Amersham Pharmacia).
Indirect immunofluorescence
Replicon cells grown on coverslips in 6-well plates were fixed,
washed and incubated with the primary antibody diluted 1:1000 in
PBS, 2% bovine serum albumin (BSA), 1.2% Triton X-100 for 2 h
at room temperature. After rinsing in PBS, cells were incubated for 2
h at RT with a rhodamine-conjugated anti-rabbit antibody (Jackson
ImmunoResearch) diluted 1:100 in PBS/0.5% BSA. After rinsing, the
coverslips were mounted onto a microscope slide with 90% glycerol,
200 mM Tris–HCl, pH 8, 0.02% sodium azide, 2% DABCO
(Calbiochem, Juro AG, Luzern, Switzerland).
Cell toxicity
Cells (4000) were treated with SCH446211 at concentrations ranging
from 50 mM to 10 nM in 96-well plates. SCH446211 was refreshed
every day for the first 3 days and once for the last 3 days during the
6 day incubation period. The MTS assay (Promega) was performed at
various time points up to 6 days.
Results
Structural analysis
SCH446211 has unique features that can lead to enhanced activity
in both enzyme and replicon assays. Different from BILN 2061,
which is a macrocyclic inhibitor occupying the P3 to P1
0 area of
the enzyme surface, SCH446211 contains a a-ketoamide electro-
philic trap (Figure 1a). Compared with VX-950 and SCH503034,
which are peptidomimetric inhibitors spanning from P4 or P3
to P1
0, respectively, SCH446211 extends from P3 towards the
P2
0 side of the active site (Figure 1b). The peptidic core of
SCH446211 binds to the protease through a series of hydrogen
bonding interactions. Crystallographic analysis shows that in
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Figure 1. SCH446211 chemical structure (a) and X-ray structure of SCH446211 bound to protease (b). Time course of peptide hydrolysis by the single chain
HCV NS3 protease in the presence of SCH446211 (c). The reaction was initiated by adding SCH446211 and enzyme mixture to substrate (see the Materials and
methods section).
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addition to the covalent bond formed after the attack of Ser-139 to
the ketoamide moiety, Thr-42, Lys-136 and Ala-157 also form
hydrogen bonds with SCH446211. The P0 residue wraps around
the side chain of lysine 136. Most notably, the P1
0–P20 moiety
forms a C-clamp locking Lys-136 in place,23,24 resulting in
extensive hydrophobic interaction that can be translated into
potent binding activity.
In vitro inhibition of NS3 protease
SCH446211 inhibited NS3 cleavage of the chromophore PAP-
linked peptide substrate in a time- and dose-dependent manner
(Figure 1c). The inhibitor binding constant K*i was estimated to be
3.8 – 0.4 nM (n = 18, 95% CI 3–6 nM). Human neutrophil
elastase (HNE) is also a serine protease which prefers a hydro-
phobic residue at the P1 position. The binding constant of
SCH446211 to HNE is estimated to be 1.5 – 0.2 mM (n = 3, 95%
CI 1.0–2.2 mM), 1000-fold weaker compared with that to HCV
protease.
Ex vivo potency of SCH446211
SCH446211 binds to HCV NS3 protease and blocks polyprotein
processing which results in inhibition of HCV RNA replication.
The clone 16 dicistronic replicon cells were dosed with
SCH446211 at concentrations from 5 mM to 10 nM every 24 h
for 3 days. Dose–response curves were generated and the drug
concentrations necessary to suppress replicon RNA level by 50%
(IC50) and 90% (IC90) were estimated to be 40 – 30 nM (95% CI)
and 100 – 40 nM (95% CI) (n = 17). A representative experiment
is shown in Figure 2(a). SCH446211 was also evaluated in three
independent dicistronic replicon clones, monocistronic replicon
cells (containing only HCV IRES, kindly provided by
R. Bartenschlager) as well as full-length replicon cells25 and the
results were comparable (data not shown).
By in situ hybridization, HCV replicon RNA was inhibited by
50% (P < 0.001) and 90% (P < 0.001) when treated with 50 and
100 nM SCH446211, respectively (Figure 2b), as compared with
untreated cells. Similar results were obtained with different
replicon clones (data not shown).
With the inhibition of HCV RNA replication, the non-
structural proteins expressed from HCV replicon genome were
also reduced. Immunoblot analysis with antibodies against HCV
NS3 and NS5B indicated that increasing concentrations of
SCH446211 were associated with a progressive decrease in both
proteins (Figure 3a, left and middle panels), and the levels of
b-actin remained constant (Figure 3a, right panel). The decrease
in both viral protein expression levels started from 50 nM
SCH446211, and continued in a dose-dependent manner. How-
ever, trace amounts of NS5B were still recognized by specific
antibodies at 500 nM of SCH446211, most likely due to
incomplete degradation of existing proteins.
Immunofluorescence assays were carried out using the anti-
NS3 polyclonal antibody. In the absence of the drug, the antibody
revealed a granular staining pattern that surrounded the nucleus
and extended through the cytosol (Figure 3b). No nuclear or
plasma membrane staining was observed. The fluorescence signal
showed a strong decrease upon incubation with increasing
concentrations of SCH446211. The most dramatic decrease was
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Figure 2. SCH446211 inhibits HCV replication in subgenomic replicon cells. (a) Real-time RT–PCR analysis of replicon RNA. The cells containing
HCV replicon were treated with SCH446211 at concentrations from 5 mM to 10 nM for 72 h. Cells were lysed at the end of treatment and the HCV
RNA level was measured relative to GAPDH RNA. The difference in threshold cycle number between HCV RNA and GAPDH RNA (DCT) was plotted
against the concentration of SCH446211. IC50 and IC90 are determined, respectively, as the concentrations corresponding to 1 and 3.2 DCT increase from
the baseline as determined with no drug control. (b) Detection of HCV RNA by radioactive in situ hybridization. Top: cells were fixed and stained
with haematoxylin and eosin after 72 h of incubation in the presence of DMSO or of increasing concentrations of SCH446211, as specified. Original
magnification, ·100. Bottom: Quantitative detection of HCV RNA (expressed as average number of silver grains per cell – SD) by radioactive in situ
hybridization.
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observed between 50 and 100 nM, whereas no signal was detected
at 500 nM.
SCH446211 acts rapidly and eliminates HCV RNA from
replicon cells
Time course studies which followed the HCV replicon RNA
levels showed that replicon RNA started to decrease after 24 h of
SCH446211 treatment. The increase in potency for a given dose
over time reflects the decay of existing RNA. Based on the time
course of 50· IC90 dose, the replicon RNA half-life is estimated to
be 12 h (Figure 4).
To assess the effect of prolonged exposure of replicon cells
to SCH446211, clone 16 cells were dosed with 0.8·, 5· and 50·
IC90 SCH446211 in the absence of G418 selection and total RNA
was isolated at days 6, 11 and 14. Replicon RNA was below
detection limit in the samples treated with 5· and 50· IC90 on day
14, estimated to be <0.1 copy per cell. When 0.5 mg/mL of G418
was added to cells treated with 5· and 50· IC90, no cells survived
the selection, indicating cure of replicon RNA from these cells.
SCH446211 did not show toxic effects on the cells. No
changes in morphology and growth rate was noted when clone
16 cells were treated with up to 10 mM of SCH446211 during the
14 day study. In a second study, cells were treated with up to
50 mM of SCH446211 for 6 days and no cytotoxicity was
observed by the MTS assay (data not shown).
When G418 was added to the SCH446211 treated cell culture
to select for resistant replicon cells, cells were isolated only from
the replicon cells dosed with 0.8· IC90, not at 5· or higher doses,
indicating that higher doses may have advantages in reducing
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Figure 4. SCH446211 acts quickly on replicon cells. Replicon cells were
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RT–PCR analysis.
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resistance and/or highly resistant replicon may be less fit in the
presence of cured cells. Others have reported resistance at higher
doses.26 It is possible that the lack of G418 in the first 2 weeks of
treatment, which applied no selection pressure on replicon cells,
favoured the growth of the cured replicon cells in culture over
cells bearing replicon RNA. The IC90 of the resistant cells was
measured to be 700 nM, 7-fold increase compared with the
parental replicon cells. Sequence analysis of the RT–PCR
products from the NS3 protease domain indicated mixed
populations at several amino acid positions including the
previously reported A156,27,28 confirming that SCH446211
inhibited NS3 protease.
Discussion
Since currently available treatments for HCV result in a
permanent cure in only 60% of patients and are often con-
traindicated or poorly tolerated,2 the development of alternative,
efficacious antivirals is warranted. Several compounds have been
reported to block the NS3 protease activity. They include both
peptide (i.e. substrate-based)30–38 and non-peptide39–41 inhibitors,
which may bind either to the S site or to the prime site,32,33
generally not used by natural substrates. In addition, short RNA
molecules have also been reported to inhibit the NS3 protease
activity.42–44 Recently, small molecular protease inhibitors were
shown to inhibit HCV RNA replication in replicon cells37,38
and proof-of-concept clinical trials have been reported.18,19
SCH446211 is a new a-ketoamide-derived, substrate-based
inhibitor of the HCV serine protease. Its potency was also
confirmed with the newly developed HCV infection system and
its EC50 in the infection system was reported to be 190 nM.
45
SCH446211’s extended P1
0–P20 interaction with NS3 protease
is translated into tight binding activity to NS3 protease and
potent antiviral activity in replicon cells. Its binding constant is
3.8 – 0.4 nM and its IC90 is 100 – 40 nM (95% CI). In comparison,
VX-950 and SCH503034, which are also peptidomimetric
inhibitors, respectively, spanning from P4 or P3 to P1
0, have
binding constants of 7 nM and 14 – 1 nM, respectively.46,47 In the
same 72 h replicon assay used to test SCH446211, the IC90
for SCH503034 was reported to be 400 nM (95% confidence
interval, 200–700 nM; n = 23).47 The IC90 for VX-950 was
determined as 830 – 190 nM in a 48 h replicon assay.46 This
information is potentially a useful guide for future development of
potent inhibitors against HCV NS3 protease. This versatility of
NS3 inhibitors may pave the way to therapeutic combinations,
thus minimizing the risk of selection for drug-resistant viral
variants.
A156T/V and R109K were identified as major resistance
mutations to SCH446211 in the genotype 1b replicon cells.25
R109K was a novel resistance mutation against SCH446211 and
it conferred moderate level (3-fold) resistance. This mutation
remains sensitive to VX-950 and SCH503034.25 The lack of
cross-resistance to VX-950 and SCH503034 was expected as the
unique feature of SCH446211 was its extension toward the P0
side of the active site and interaction with R109. VX-950 and
SCH503034 do not make contacts with this residue and therefore
their potency was not affected.25 A156T/V conferred >100-fold
resistance to VX-950 and BILN2061 as well as SCH503034.28,48
This mutation also reduced replicon fitness to 3–5% versus
wild-type. The same mutation only conferred 20-fold resistance
to SCH446211. The difference in resistance to different
compounds by the same mutation may be explained by that
SCH446211 derived its binding energy from contacts from both P
and P0 sides of the enzyme.25 Owing to its extended contacts with
NS3 protease, SCH446211 may encounter few strong resistant
variants as they would require loss of contacts at both P and P0
sides of the enzyme.
In addition to the direct antiviral activity, SCH446211 was
shown to revert the NS3/4A mediated blockade of phosphoryla-
tion and effector activity of the interferon regulatory factor-3
(IRF-3).49,50 IRF-3 induces the expression of a variety of cellular
genes including type I IFNs,49,51 which further amplify the
antiviral response through the induction of interferon-stimulated
genes (ISGs).51 The blockade of IRF-3 activation by the HCV
NS3/4A protease may significantly affect both the host response
to viral infection and the response to IFN-a-based therapy.51,52
Thus, SCH446211 and other NS3/4A protease inhibitors may
counteract not only the cleavage function necessary to proper
processing of mature viral proteins, but also the inhibition of the
innate host immune response against HCV. Foy et al.49 have
shown the likelihood of such dual therapeutic mechanisms, since
SCH446211 both restored the host IRF-3 pathway and inhibited
viral polyprotein processing. As an additional effect, NS3/4A
inhibitors may also counteract the transforming activity of HCV.
Transfection with NS3 of different cell lines has shown that this
protein may induce tumour formation upon engrafting of
transfected cells into nude mice.53 Non-specific inhibitors of
NS3 protease eliminated the transforming activity.54,55
In conclusion, SCH446211 is a potent inhibitor of the NS3
protease and it effectively inhibits the HCV subgenomic RNA
replication. Its extended interaction with the protease active site is
associated with improved antiviral potency in replicon cells and
can be a useful guide for future development of potent inhibitors.
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